The drug, suzetrigine, will be sold under the brand name Journavx and is the first new class of pain medicine approved in ...
The drug, shown to be almost as effective as opioids for short-term pain, is the first fundamentally new kind of painkiller ...
If the attention generated by BioSpace’s coverage of this landmark approval is any indication, Americans are hungry for ...
The FDA on Thursday approved a new class of pain medication that provides an alternative to opioids. It will be sold under ...
A new painkiller that is said to be free of addiction risks may be transformative for treatment of acute pain, according to ...
The FDA has approved Journavx, a pain medication, offering a safer alternative to opioids. Learn about its benefits and side ...
Will people with acute pain want a new painkiller whose list price is $15.50 a pill when a generic prescription drug is at ...
The Food and Drug Administration (FDA) has approved Journavx™ (suzetrigine) for the treatment of moderate to severe acute pain in adults.
This milestone marks a breakthrough after unsuccessful attempts to develop painkillers without the addictive potential of opioids.
One participant in the drug trial for Journavx said it eliminated her pain without making her feel loopy or nauseous, which ...
The new non-opioid drug has been approved for the treatment of severe pain, such as that following surgery or an injury.
The FDA has approved a new non-opioid prescription medication, Journavx for adults with moderate to severe acute pain.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback